GenSight Biologics announces a successful offering for an amount over €9.2 million

• GenSight Biologics shares resume trading today
• Over €9.2 million offering of ABSA (as defined below) composed of a reserved offering aimed at specialized investors and a private placement
• More than 50% of the offering subscribed by US investors

Paris, France, May 7th, 2024, 7.30 a.m. CEST – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (the “Company“), a biopharma Company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced today the resumption of the trading of the Company’s shares following the success of its Offering (as defined below), through (i) a capital increase reserved to specialized investors and (ii) a concurrent capital increase by way of a private placement, by the issuance of new shares with warrants attached, for a total gross amount of €9,282,515.80 (excluding the future net proceeds related to the exercise of the warrants). The subscription price for one ABSA is €0.395 (the “Offering Price”). The Offering Price is the same in the two concurrent capital increases.

“This fundraising marks an inflection point in our journey and demonstrates the confidence of investors in our vision and ability to achieve our strategic objectives,” said Laurence Rodriguez, CEO of GenSight Biologics. “We are grateful to our historic investors for their continued support. We confirm plans to resume early access program in France for LHON patients in Q3 2024.“

Link to full press release: https://www.gensight-biologics.com/2024/05/07/gensight-biologics-announces-a-successful-offering-for-an-amount-over-e9-2-million/